



A Phase IB/II Study of Duvelisib in Combination with FCR (DFCR) For Frontline Therapy for Younger CLL Patients



<u>Matthew S. Davids, MD, MMSc¹</u>, David C. Fisher, MD¹, Svitlana Tyekucheva, PhD¹, Haesook T. Kim, PhD¹, Mikaela McDonough¹, John Hanna¹, Karen Francoeur, RN¹, Josie Bazemore, NP¹, Jeffrey Hellman, PA-C¹, Oreofe Odejide, MD¹, Philippe Armand, MD, PhD¹, Jon Arnason, MD², and Jennifer R. Brown, MD, PhD¹

¹Dept. of Medical Oncology, Dana-Farber Cancer Institute ²Dept. of Medical Oncology, Beth Israel Deaconess Medical Center Boston, USA

2018 EHA Annual Meeting – Stockholm, Sweden – 16 June 2018





Disclosure of affiliations

Matthew S. Davids, MD, MMSc

Consulting: Verastem, TG Therapeutics, Gilead, Pharmacyclics, Janssen, Abbvie, Genentech, MEI Pharma, Astra-Zeneca, Merck


Institutional research funding: Verastem, TG Therapeutics, Pharmacyclics, Genentech, BMS, MEI Pharma, Surface Oncology

FCR has curative potential in mutated IGHV CLL

MDACC – FCR 300 GCLLSG – CLL8 N Prog-free 100 Probability of Progression-free Survival **IGHV** mutated 49 88 Percent progression-free IGHV unmutated 126 12 75-0,6--FCR IGHV MUT patients (N=113) 50 IGHV MUT patients (N=117) p < 0.0001 25-0,2-IGHV UNM patients (N=197) --FCR FC IGHV UNM patients (N=195) -----______ p < 0.001 by log-rank test 0,0-0 12 13 14 15 16 0 2 3 8 9 10 60 72 84 Ó 12 96 24 Time (Years) Months on Study

Bone marrow MRD negativity is likely a prerequisite for cure







Study Rationale

Our goal is to increase the curative potential of FCR for younger, fit CLL patients, including those with high risk disease markers

Duvelisib is an oral inhibitor of PI3K- δ and PI3K- γ



duvelisib




δ (delta)	duvelisib	idelalisib
Biochemical Activity (K _D)	23 pM	273 pM
Cellular Activity (IC₅₀) RAJI cells stimulated with anti-IgM	0.36 nM	4.9 nM

γ (gamma)	duvelisib	idelalisib
Biochemical Activity (K _D)	243 pM	85,700 pM
Cellular Activity (IC₅₀) RAW264.7 cells stimulated with C5a	19.6 nM	520 nM

Duvelisib is highly active across CLL risk groups

Relapsed/Refractory CLL/SLL



18 additional treatment-naïve CLL patients received duvelisib ORR was 83%

Background	
Hypothesis	

The addition of duvelisib to FCR (DFCR) will increase the rate of CR with BM MRD (-) for frontline CLL treatment, with an acceptable safety profile

Methods

A phase Ib/II investigator-initiated study of duvelisib + FCR (DFCR) for younger, previously untreated patients with CLL

Endpoints

Primary

• Rate of CR with BM MRD negativity 2 mo. post FCR completion

Secondary

- Clinical response: ORR, CR, PR, PFS, EFS, and remission duration
- Rates of best response and best BM and PB MRD-negativity
- Safety/Tolerability
- Association of established CLL prognostic factors (e.g. FISH cytogenetics, *IGHV*, *TP53* and *NOTCH1* mutation) with clinical response

Exploratory

- Association of novel prognostic factors such as BH3 profiling with response
- Comparison of MRD assessment by 4-color flow cytometry vs. Adaptive clonoSEQ assay

Methods

A phase Ib/II investigator-initiated study of duvelisib + FCR (DFCR) for younger, previously untreated patients with CLL

Key Eligibility Criteria

Inclusion


- Confirmed diagnosis of previously untreated CLL/SLL
- Indication for treatment per 2008 IW-CLL criteria
- Age \geq 18 years and \leq 65
- Adequate renal and hepatic function, ECOG performance status <1

Exclusion

- History of alcohol abuse, chronic hepatitis, or other chronic liver disease (other than direct CLL liver involvement)
- Unable to receive prophylactic treatment for PJP
- Known CNS involvement

Methods

A phase Ib/II investigator-initiated study of duvelisib + FCR (DFCR) for younger, previously untreated patients with CLL



G-CSF and PJP/HSV/VZV prophylaxis mandatory for all patients

- A standard 3 + 3 phase Ib design with 2 dose levels of duvelisib with monthly cycles
- 25 mg qd (starting level) and 25 mg bid, then a phase II expansion cohort
- Standard toxicity assessments by CTCAE v4.03 and 2008 IW-CLL
- Response evaluations by 2008 IW-CLL: after 3 cycles, 2 mo. after final FCR, then q6 mo.
- All CRs were confirmed with CT and bone marrow biopsy
- MRD: assessed by 4-color flow cytometry (sensitivity 10⁻⁴)

Baseline Patient Characteristics (fully enrolled, n=32)

- Median age at enrollment: 55 years (range 45-65)
- Male: 69%

• FISH [#] :	del (17p)*	del(11q)	Trisomy 12	del(13q)	Del(6q)	Normal
	n=3 (9%)	n=8 (25%)	n=7 (22%)	n=14 (44%)	n=3 (9%)	N=6 (19%)
	#some patients had >1 FISH abnormality, *all with complex karyotype					

- IGHV: 18/32 (56%) unmutated, ZAP-70: 19/31 (61%) pos.
- Somatic Mutations: TP53 mut without del(17p) n=2, NOTCH1 mut n=1
- Median β2M: 4.0 mg/L (range 2.2-8.1)
- 41% with Rai stage III/IV disease
- Median of 80% bone marrow involvement (range 0-95%)
- Baseline counts (median, range):
 - WBC: 97 K/uL (2.7-595)
 - Hgb: 11 g/dl (5.8-15.9)
 - Plts: 115 K/uL (19-377)

Safety Analysis (n=32)

- Only 1 DLT in dose escalation (Gr 3 febrile neutropenia at 25 mg qd)
- RP2D of duvelisib given with FCR: 25 mg bid

All grade hematologic toxicity: -neutropenia: 59% (50% gr 3/4)	All grade immune-mediated toxicities: -transaminitis: (34%, 28% gr 3/4) -inflammatory arthritis: (9%, all gr2)
- thrombocytopenia: 65% (34% gr 3/4)	-colitis: (6%, 1 gr2, 1 gr3)
- anemia: 38% (16% gr 3/4)	-pericarditis and pancreatitis: (3%, gr2)

Other all grade non-heme toxicities:

- nausea: (72%, all gr1/2)
- fatigue (69%, 3% gr3)
- fever (53%, all gr1/2)
- diarrhea (47%, 3% gr3)

- anorexia: (34%, all gr1/2)
- **vomiting** (28%, all gr 1/2)
- pruritus: (16%, 3% gr3)
- CMV reactivation (6%, both gr2)

Safety Analysis (n=32)

Additional SAEs:

- Pneumonia (n=6 (19%), including 3 cases of PJP despite prophy.)
- Gr3 febrile neutropenia (n=6, (19%), and sinusitis, zoster, CMV infxn, rash, AIHA (n=1 each)
- Secondary malignancies:
 - Gr5 metastatic melanoma (n=1, 10 mo. after completing FCR, not on duvelisib)
 - Gr5 glioblastoma multiforme (n=1, within 3 mo. after completing duvelisib maintenance)
 - Gr4 MDS (n=1, within 3 mo. after completing duvelisib maintenance)

Additional safety information

- Rate of Gr 3 or higher infection: 9/32 (28%)
- 14/32 (44%) of pts received steroids for toxicity management
- 8 pts required dose reduction (chemo n=4 (13%), duvelisib n=6 (19%), both n=2 (6%))
- #DFCR cycles: median of 5.5 cycles (6 (n=14), 5 (n=3), 4 (n=4), 3 (n=3), 1 (n=4))

DFCR Primary Efficacy Analysis

(31 patients evaluable for 1° endpoint)

	C4D1	Primary Endpoint (2 mo. post-FCR)	Best Response
ORR	94% (29/31)	94% (29/31)	94% (29/31)
PR	74% (23/31)	68% (21/31)	42% (13/31)
CR/CRi	19% (6/31)	26% (8/31)	52% (16/31)
CR with BM MRD neg.	13% (4/31)	26% (8/31) [*]	55% (16/29)
BM MRD neg.	54% (15/28)	67% (18/27)	76% (22/29)


- All patients who achieved CR at primary endpoint also were BM MRD neg.
- 53% (10/19) of PR patients were BM MRD neg. at primary endpoint, most w/ LN <2.5 cm
- Responses deepened with duvelisib maintenance

*primary endpoint

DFCR: Response deepens over time in both *IGHV* mutated and *IGHV* unmutated patients


IGHV Mutated

IGHV Unmutated



<u>Best BM MRD negativity rate: 76% (22/29)</u>
 -IGHV-M: 83% (10/12), *IGHV*-U: 71% (12/17)

DFCR: Survival analyses



- With a median follow-up of 24.5 months (range 6.9-46):
 - 2 year PFS and OS: 97%

Efficacy Analysis – Additional Data

- All 3 pts with complex karyotype with del(17p) responded, including 1 with MRD neg. CR, and 2 with MRD pos. PR
- 2 patients have progressed
 - 1 with CK/del(17p) who died due to Richter's Syndrome 29 mo. after starting on study
 - 1 with del(11q)/unmut *IGHV* with asymptomatic progression 6 mo. after completing duvelisib maintenance, still not requiring therapy
- 8 patients completed a full 2 years of duvelisib maintenance, 5 of these
 8 remain progression free (median follow-up since study start 44 mo.)

DFCR: Conclusions

- Rate of best BM MRD neg. of 76% is significantly higher than historical data with FCR and similar to the ibrutinib + FCR regimen (Davids et al., ASH, 2017)
- High rates of BM MRD neg. were observed even in higher risk CLL such as unmutated *IGHV*, and responses deepened on duvelisib maintenance
- DFCR toxicities are comparable to duvelisib and FCR individually, with infectious, immune-mediated toxicities, and secondary malignancies observed
- DFCR is an effective regimen for the initial therapy of younger, fit CLL patients who desire a time-limited therapy with potential for long term remission







Acknowledgments

DFCI CLL Center:

Jennifer Brown

- Jeff Hellman / Josie Bazemore
- Elizabeth Coughlin / Jamie Ye
- Mikaela McDonough

Monique Girard

- Megan Hiserodt / Mackenzie Wiggin John Daley / Suzan Lazo-Kallanian Caroline Harvey
- **Stacey Fernandes**
- **Timothy Lehmberg**
- Victoria Cotugno
- Kevin Hoang / Harrison Bai

Infinity

Verastem

Patients and their families



Dana-Farber Cancer Institute



Boston, MA USA

American Society of Clinical Oncology (Career Development Award)

Workshops: ASH CRTI AACR/ASCO Vail Workshop

The Davids Lab

Translational CLL Research

davidslab.dana-farber.org

